Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer

被引：0
|
作者：
Gunderson, Camille C. [1 ]
Moore, Kathleen N. [1 ]
机构：
[1] Univ Oklahoma, Hlth Sci Ctr, Stephenson Oklahoma Canc Ctr, Oklahoma City, OK 73104 USA
来源：
FUTURE ONCOLOGY | 2015年 / 11卷 / 05期
关键词：
BRCA mutation; homologous recombination pathway; PARP inhibitor; olaparib; ovarian cancer; POLY(ADP-RIBOSE) POLYMERASE; EPITHELIAL OVARIAN; MAINTENANCE THERAPY; MAMMARY-TUMORS; MUTANT-CELLS; OPEN-LABEL; COMBINATION; CHEMOTHERAPY; PACLITAXEL; PHASE-2;
D O I：
10.2217/FON.14.313
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Olaparib (Lynparza (TM); AZD2281) is a potent PARP-1 and PARP-2 inhibitor with biologic activity in ovarian cancer as well as other solid tumors. It has been tested in Phase I and II trials and has single-agent activity in both germline BRCA mutated and sporadic ovarian cancer. Phase III trials assessing the efficacy of olaparib in the maintenance setting following first line and platinum-sensitive recurrence are underway for patients with a germline BRCA mutation, given the inherent molecular compatibility with the drug's mechanism of action.
引用
收藏
页码：747 / 757
页数：11
相关论文
共 50 条
  • [1] Olaparib. PARP-1 and PARP-2 inhibitor, Oncolytic.
    Vasiliou, S.
    Castaner, R.
    Bolos, J.
    [J]. DRUGS OF THE FUTURE, 2009, 34 (02) : 101 - 105
  • [2] Olaparib: a promising PARP inhibitor in ovarian cancer therapy
    Ying Chen
    Lei Zhang
    Quan Hao
    [J]. Archives of Gynecology and Obstetrics, 2013, 288 : 367 - 374
  • [3] Olaparib: a promising PARP inhibitor in ovarian cancer therapy
    Chen, Ying
    Zhang, Lei
    Hao, Quan
    [J]. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2013, 288 (02) : 367 - 374
  • [4] PARP-1 and PARP-2 activity in cancer-induced cachexia: potential therapeutic implications
    Barreiro, Esther
    Gea, Joaquim
    [J]. BIOLOGICAL CHEMISTRY, 2018, 399 (02) : 179 - 186
  • [5] Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies
    Yelamos, Jose
    Moreno-Lama, Lucia
    Jimeno, Jaime
    Ali, Syed O.
    [J]. CANCERS, 2020, 12 (02)
  • [6] PARP-1 and PARP-2: New players in tumour development
    Yelamos, Jose
    Farres, Jordi
    Llacuna, Laura
    Ampurdanes, Coral
    Martin-Caballero, Juan
    [J]. AMERICAN JOURNAL OF CANCER RESEARCH, 2011, 1 (03): : 328 - 346
  • [7] Olaparib, PARP1 inhibitor in ovarian cancer
    Marchetti, Claudia
    Imperiale, Ludovica
    Gasparri, Maria Luisa
    Palaia, Innocenza
    Pignata, Sandro
    Boni, Terenzio
    Bellati, Filippo
    Panici, Pierluigi Benedetti
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (10) : 1575 - 1584
  • [8] The Role Of PARP-1 And PARP-2 In Contact Hypersensitivity Reaction
    Brunyanszki, A.
    Hegedu, C.
    Szanto, M.
    Gergely, P.
    Virag, L.
    Bai, P.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2009, 129 : S14 - S14
  • [9] Characterization of PARP-1 and PARP-2 function at heterochromatin domains
    Quenet, D.
    [J]. MOLECULAR BIOLOGY OF THE CELL, 2016, 27
  • [10] The Role of PARP-1 and PARP-2 Enzymes in Metabolic Regulation and Disease
    Bai, Peter
    Canto, Carles
    [J]. CELL METABOLISM, 2012, 16 (03) : 290 - 295
12345